Mechanism of Action
CRLR / RAMP Receptor System
Adrenomedullin binds to the calcitonin receptor-like receptor (CRLR) in complex with receptor activity-modifying proteins RAMP2 or RAMP3. These receptor complexes couple to Gs proteins, elevating intracellular cAMP and activating PKA. In vascular smooth muscle, this cascade causes relaxation and vasodilation. In endothelial cells, cAMP signaling strengthens tight junctions and reduces permeability.
Nitric Oxide Pathway
Beyond cAMP signaling, adrenomedullin activates eNOS in endothelial cells, generating NO and contributing to vasodilation. The dual cAMP/NO mechanism provides robust vascular relaxation. Additionally, ADM activates PI3K/Akt pathways that promote endothelial survival and reduce apoptosis.
Anti-inflammatory and Barrier Functions
Adrenomedullin suppresses NF-kB activation and reduces production of pro-inflammatory cytokines including TNF-alpha and IL-6. Critically, ADM maintains vascular endothelial barrier integrity by upregulating VE-cadherin and tight junction proteins. Loss of endogenous ADM signaling is associated with vascular leak and inflammation seen in severe infections and organ injury.
Research Summary
Sepsis and Critical Illness
HumanPlasma ADM levels surge in sepsis and correlate with severity and outcomes. Phase II trials of adrecizumab (anti-ADM antibody that modulates ADM bioavailability) showed improved outcomes in septic shock patients with high ADM levels. Exogenous ADM infusion also showed hemodynamic stabilization in early sepsis trials.
Heart Failure
HumanADM infusion reduced pulmonary capillary wedge pressure and systemic vascular resistance in heart failure patients without adverse effects on heart rate. Plasma ADM levels independently predict heart failure mortality, and the ADM system is now considered a therapeutic target alongside established neurohormonal pathways.
Wound Healing
AnimalTopical or local ADM application accelerated wound closure in diabetic and normal animal models through angiogenesis promotion, reduced inflammation, and enhanced fibroblast proliferation. These findings support investigation of ADM in chronic wound therapy.
Calculate your Adrenomedullin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Cardiovascular research | 2-10 ng/kg/min | Continuous IV infusion x 30-60 min | Intravenous |
| Wound healing model | 100-500 ng/wound | Daily topical x 7-14 days | Local application |
Native ADM is primarily researched via IV infusion due to short plasma half-life. Subcutaneous protocols exist in animal models.
Interactions
Safety Profile
Adrenomedullin infusion has been well tolerated in clinical trials. The main dose-limiting effect is blood pressure reduction, which is pharmacologically expected given its vasodilatory mechanism. Heart rate increases were mild and transient. No significant arrhythmias or organ toxicity were observed in Phase II trials. Short plasma half-life limits systemic accumulation.
References
- [1]Kitamura K, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553-560.
- [2]Hirata Y, et al. Hemodynamic effects of adrenomedullin in patients with chronic heart failure. Am Heart J. 1999.
- [3]Geven C, et al. Adrenomedullin in sepsis and septic shock. Shock. 2018;50(4):360-374.